On verge of gaining approval for apabetalone for treatment of C-19, RVX is all in based on preliminary in vitro studies, and long standing established safety protocols in vivo human coronary studies.
S
No communication, what's going on
T
Plain and simple get a CEO that can make this happen and the stock would be over $5. Investors are tired same BS year after year and Hess collecting over 600k for both companies!!!!
E
“We are excited to be moving forward with a larger trial of apabetalone in PAH patients.” Oh really?! I've heard that one before, LOL. With what money? With a partner? In two years from now we probably still won't know. Another typical forward looking statement from the big mouth of lies.
E
The virtual investor conference seems to have gone really well, LOL
M
With no value enhancing PR, this is going to drift lower & lower. I may be adding some more this week, at this sp the risks are minimal
M
If you believe in this company, load up!
o
CC was clear as mud. Failed on primary endpoint, no news on secondary endpoints, and mention of an academic embargo in place on data which will be released at AHA. McCafrrey also touched on how important a compound apabetalone is in a partnering environment. He mentioned that the top 10 shareholders hold 70% of the shares and they are all in. He recommended the other 30% wait out the volatility.
Never heard anything like it before.
A
Very disappointed in McCaffery’s explanation. Management owes its investor more than “Opps”. Based on his comments he has had discussions with the major investors prior to this announcement and he has an obligation to disclose any plans that he disclosed to these investors to the rest us. Many investors have been waiting years for this day and the webinar left more questions than answers.
G
Secondary Endpoints unveiled ? CC on BetonMace Nov 18. Bullish again it appears.
b
Trading pattern downwards is identical to AMRN this time last year in September before their data came out and the stock went from $2-$20 in a day. I feel it would be a cataclysmic shock if the data does not come back positive based on phase 2 where the RR was between 55-62% and the p value was .0001. On phase 3 all we need is RR at 30% or better and p value .005. IF data comes back positive in coming days, (September 30 latest) this is the final buying opportunity of a lifetime. $10 minimum day of data release if positive. Frankly I believe $15 very possible. Furthermore, I would NOT sell off the news assuming its positive due to all the major conferences they will be presenting at in coming months. The more awareness rvx gets off positive data the more shares will appreciate. Not selling a share for anything under $15 a share on positive news.
b
Olny 4 business days left, or sooner! Gotta say, very excited and anxious. Wild that years of research and investing in an idea like this comes down to 1 single day. I feel it will be well worth it.
C
Conference today was very good. Stock price is stalled. If we were on Nasdaq we would be at least $7 when looking at other similar stories
Resverlogix is to release topline Phase 3 results from the BETonMACE phase 3 clinical trial on September 30. Primary endpoint is cardiovascular death, non-fatal
Resverlogix is to release topline Phase 3 results from the BETonMACE phase 3 clinical trial on September 30. Primary endpoint is cardiovascular death, non-fatal
seekingalpha.com
T
Great day. Blue sky ahead. Uplisting news before revealing top line?
Roth Capital Believes Resverlogix (TSX: RVX) Still Has Room to Grow | Analyst Ratings
www.analystratings.com
o
This stock is the ultimate lottery ticket.
Assure focused on the general CVD population and was trending in the right direction. My recollection is that it would have hit its primary endpoint had it been just a few months longer.
BETonMACE is focused on diabetic CVD patients and that is a nice market on its own. Assuming it is successful, what sort of PIII trial would be required to make another run at the massive general CVD population? How long would it take?
The Montreal cognitive test (MOCA) is a secondary endpoint of BETonMACE. If that endpoint was to be hit would the Zenith Capital rights start actively trading?
RVX offers a potential double grand slam here with only five months to wait. Don't underestimate how high the stock could go if BETonMACE is successful and apabetalone is identified as the first drug which safely raises HDL. Esperion was trading at a $2B market cap not long ago on yet another LDL-reducing compound in a very crowded market.
a
It is still a waiting game for 250 events. Management was too optimistic for the 250 events to occur by the end of last year. Management is obviously withholding where the current number is, but I can assure you they are well ahead of 220 events. It is my opinion that they are between 230 to 240 events. They can not control when the remaining events will occur, that's why they have pushed that projection to June. I believe and hope that the 250 mark will be hit sometime in the second quarter before June. After that, it will be 3 to 4 months for the evaluation of the data to occur. All told I believe we are looking at September which would be a very nice birthday present for me. Am I disappointed this far in the price per share right now, yes, unfortunately it is par for the course with small biotech companies. I think part of the reason is that they have not gotten the attention that they should have gotten in the biotech investment community. That should all change soon if the results are positive. Do I believe in Resverlogix, I do, that's why I've owned for so many years. Our patience will hopefully pay off in a big way. Furthermore, for those of us which have owned Resverlogix for many years and have shares of Zenith, I believe good things will come from this privately held company. They have partnered up with Pfizer in developing and starting their phase trials in various other diseases. I really do believe that good things are in the near future. Stay Resverlogix Strong !
S
This Company will hit 5 USD , the company going to secure FDA approval in less than 18 months and will be bought by giant pharmaceutical companies, their Molecules is excellent and promising ,
Another typical forward looking statement from the big mouth of lies.
Never heard anything like it before.
https://www.analystratings.com/articles/roth-capital-believes-resverlogix-tsx-rvx-still-has-room-to-grow/
Assure focused on the general CVD population and was trending in the right direction. My recollection is that it would have hit its primary endpoint had it been just a few months longer.
BETonMACE is focused on diabetic CVD patients and that is a nice market on its own. Assuming it is successful, what sort of PIII trial would be required to make another run at the massive general CVD population? How long would it take?
The Montreal cognitive test (MOCA) is a secondary endpoint of BETonMACE. If that endpoint was to be hit would the Zenith Capital rights start actively trading?
RVX offers a potential double grand slam here with only five months to wait. Don't underestimate how high the stock could go if BETonMACE is successful and apabetalone is identified as the first drug which safely raises HDL. Esperion was trading at a $2B market cap not long ago on yet another LDL-reducing compound in a very crowded market.